Jean Powers

1.8k total citations
32 papers, 1.3k citations indexed

About

Jean Powers is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Jean Powers has authored 32 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 12 papers in Molecular Biology. Recurrent topics in Jean Powers's work include Lung Cancer Treatments and Mutations (8 papers), Chronic Lymphocytic Leukemia Research (7 papers) and PI3K/AKT/mTOR signaling in cancer (5 papers). Jean Powers is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Chronic Lymphocytic Leukemia Research (7 papers) and PI3K/AKT/mTOR signaling in cancer (5 papers). Jean Powers collaborates with scholars based in Canada, United States and New Zealand. Jean Powers's co-authors include Elizabeth A. Eisenhauer, C. Tom Kouroukis, Michael Crump, Lesley Seymour, Randy D. Gascoyne, Frances A. Shepherd, James R. Wright, Scott A. Laurie, Wendy Walsh and Robert Turner and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Cancer.

In The Last Decade

Jean Powers

30 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jean Powers Canada 17 561 556 383 356 270 32 1.3k
Joanne Lager United States 17 563 1.0× 439 0.8× 389 1.0× 215 0.6× 389 1.4× 37 1.2k
Maja J.A. de Jonge Netherlands 19 865 1.5× 848 1.5× 420 1.1× 195 0.5× 170 0.6× 40 1.6k
David Demanse Switzerland 16 1.2k 2.2× 699 1.3× 630 1.6× 255 0.7× 363 1.3× 41 1.8k
He Huang China 19 537 1.0× 480 0.9× 159 0.4× 207 0.6× 55 0.2× 78 1.4k
Jane Robertson United Kingdom 22 816 1.5× 1.3k 2.3× 510 1.3× 176 0.5× 65 0.2× 57 2.0k
Andrew Dorr United States 16 737 1.3× 356 0.6× 147 0.4× 86 0.2× 124 0.5× 37 1.0k
Carmen Kahatt Spain 19 1.1k 2.0× 849 1.5× 461 1.2× 176 0.5× 43 0.2× 97 2.0k
Scott Z. Fields United States 21 1.2k 2.2× 1.5k 2.7× 205 0.5× 165 0.5× 106 0.4× 46 2.3k
Irina Linkov United States 15 531 0.9× 598 1.1× 351 0.9× 257 0.7× 52 0.2× 27 1.5k
C.J.A. van Moorsel Netherlands 14 445 0.8× 644 1.2× 333 0.9× 116 0.3× 79 0.3× 16 1.1k

Countries citing papers authored by Jean Powers

Since Specialization
Citations

This map shows the geographic impact of Jean Powers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean Powers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean Powers more than expected).

Fields of papers citing papers by Jean Powers

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean Powers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean Powers. The network helps show where Jean Powers may publish in the future.

Co-authorship network of co-authors of Jean Powers

This figure shows the co-authorship network connecting the top 25 collaborators of Jean Powers. A scholar is included among the top collaborators of Jean Powers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean Powers. Jean Powers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Seftel, Matthew D., John Kuruvilla, Versha Banerji, et al.. (2016). The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group. Leukemia & lymphoma. 58(6). 1358–1365. 34 indexed citations
2.
Ghoddusi, Majid, Keith R. Pierce, Jean Powers, et al.. (2016). FGFR2b represents a novel target for treatment of urothelial cancer. European Journal of Cancer. 69. S143–S143.
3.
Eigl, Bernhard J., Scott North, Eric Winquist, et al.. (2015). A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195. Investigational New Drugs. 33(4). 969–976. 54 indexed citations
4.
Chu, Quincy, Torsten O. Nielsen, Thierry Alcindor, et al.. (2015). A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas—NCIC-CTG IND 200. Annals of Oncology. 26(5). 973–981. 41 indexed citations
5.
Ellis, Peter, Frances A. Shepherd, Scott A. Laurie, et al.. (2014). NCIC CTG IND.190 Phase I Trial of Dalotuzumab (MK-0646) in Combination with Cisplatin and Etoposide in Extensive-Stage Small-Cell Lung Cancer. Journal of Thoracic Oncology. 9(3). 410–413. 16 indexed citations
6.
7.
Seftel, Matthew D., John Kuruvilla, Versha Banerji, et al.. (2014). A Phase II Study of AT7519M, a CDK Inhibitor, in Patients with Chronic Lymphocytic Leukemia: NCIC CTG Trial IND.193. Blood. 124(21). 5670–5670. 3 indexed citations
8.
Razak, A.R. Abdul, Sébastien J. Hotte, Lillian L. Siu, et al.. (2011). Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours. British Journal of Cancer. 104(5). 756–762. 52 indexed citations
9.
Kouroukis, C. Tom, Michael Crump, Neil Chua, et al.. (2011). A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172). Leukemia & lymphoma. 52(3). 394–399. 46 indexed citations
10.
Chen, Christine, C. Tom Kouroukis, Darrell White, et al.. (2009). Bortezomib in Relapsed or Refractory Waldenström's Macroglobulinemia. Clinical Lymphoma & Myeloma. 9(1). 74–76. 23 indexed citations
11.
Crabb, Simon J., Demetris Patsios, Eric E. Sauerbrei, et al.. (2008). Tumor Cavitation: Impact on Objective Response Evaluation in Trials of Angiogenesis Inhibitors in Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 27(3). 404–410. 118 indexed citations
12.
13.
Chen, Christine I., C. Tom Kouroukis, Darrell White, et al.. (2007). Bortezomib Is Active in Patients With Untreated or Relapsed Waldenström's Macroglobulinemia: A Phase II Study of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology. 25(12). 1570–1575. 126 indexed citations
14.
Belch, Andrew R., C. Tom Kouroukis, Michael Crump, et al.. (2006). A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Annals of Oncology. 18(1). 116–121. 126 indexed citations
15.
Goss, Glenwood, Lillian L. Siu, Isabelle Gauthier, et al.. (2006). A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group. Cancer Chemotherapy and Pharmacology. 58(5). 703–710. 7 indexed citations
16.
N., K., Lillian L. Siu, Holger W. Hirte, et al.. (2005). A phase I study of a second generation antisense oligonucleotide to clusterin (OGX-011) in combination with docetaxel: NCIC CTG IND.154. Journal of Clinical Oncology. 23(16_suppl). 3085–3085. 12 indexed citations
17.
Kirby, Sarah, S. Gertler, Warren Mason, et al.. (2005). Phase 2 study of T138067-sodium in patients with malignant glioma: Trialof the National Cancer Institute of Canada Clinical Trials Group. Neuro-Oncology. 7(2). 183–188. 20 indexed citations
18.
Ma, Brigette, Amit M. Oza, Elizabeth A. Eisenhauer, et al.. (2004). The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers - a study of the National Cancer Institute of Canada Clinical Trials Group. International Journal of Gynecological Cancer. 14(4). 650–658. 117 indexed citations
19.
20.
N., K., Ladan Fazli, Edward C. Jones, et al.. (2004). A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of OGX-011, a 2'methoxyethyl phosphorothioate antisense to clusterin, in patients with prostate cancer prior to radical prostatectomy. Journal of Clinical Oncology. 22(14_suppl). 3033–3033. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joanne Lager Breakdown of academic impact, for papers by Maja J.A. de Jonge Breakdown of academic impact, for papers by David Demanse Breakdown of academic impact, for papers by He Huang Breakdown of academic impact, for papers by Jane Robertson Breakdown of academic impact, for papers by Andrew Dorr Breakdown of academic impact, for papers by Carmen Kahatt Breakdown of academic impact, for papers by Scott Z. Fields Breakdown of academic impact, for papers by Irina Linkov Breakdown of academic impact, for papers by C.J.A. van Moorsel
Rankless by CCL
2026